The Association between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Noam Barda; Michal Canetti; Mayan Gilboa; Keren Asraf; Victoria Indenboim; Yael Weiss-Ottolenghi; Sharon Amit; Daniel Zubli; Ram Doolman; Ella Mendelson; Laurence S. Freedman; Yitshak Kreiss; Yaniv Lustig; Gili Regev-Yochay

doi:10.1093/cid/ciac886

The Association between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Noam Barda, Michal Canetti, Mayan Gilboa, Keren Asraf, Victoria Indenboim, Yael Weiss-Ottolenghi, Sharon Amit, Daniel Zubli, Ram Doolman, Ella Mendelson, Laurence S. Freedman, Yitshak Kreiss, Yaniv Lustig, Gili Regev-Yochay^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

The correlation between anti–severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre–fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%–59%) for each 10-fold increase in prebooster levels. Prebooster antibody levels could be used to optimally time boosters.

Original language	English
Pages (from-to)	1315-1317
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	76
Issue number	7
DOIs	https://doi.org/10.1093/cid/ciac886
State	Published - 1 Apr 2023

Funding

Funders	Funder number
Nehemia Rubin Excellence in Biomedical Research
TELEM Program of Chaim, Sheba Medical Center
Pfizer
Sheba Medical Center

Keywords

IgG levels
SARS-CoV-2
boosters
infection risk
mRNA vaccines

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/ciac886

Cite this

Barda, N., Canetti, M., Gilboa, M., Asraf, K., Indenboim, V., Weiss-Ottolenghi, Y., Amit, S., Zubli, D., Doolman, R., Mendelson, E., Freedman, L. S., Kreiss, Y., Lustig, Y., & Regev-Yochay, G. (2023). The Association between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clinical Infectious Diseases, 76(7), 1315-1317. https://doi.org/10.1093/cid/ciac886

@article{c6df4ef532ff46cb9c041c72adb703e3,

title = "The Association between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection",

abstract = "The correlation between anti–severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre–fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%–59%) for each 10-fold increase in prebooster levels. Prebooster antibody levels could be used to optimally time boosters.",

keywords = "IgG levels, SARS-CoV-2, boosters, infection risk, mRNA vaccines",

author = "Noam Barda and Michal Canetti and Mayan Gilboa and Keren Asraf and Victoria Indenboim and Yael Weiss-Ottolenghi and Sharon Amit and Daniel Zubli and Ram Doolman and Ella Mendelson and Freedman, {Laurence S.} and Yitshak Kreiss and Yaniv Lustig and Gili Regev-Yochay",

year = "2023",

month = apr,

day = "1",

doi = "10.1093/cid/ciac886",

language = "אנגלית",

volume = "76",

pages = "1315--1317",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "7",

}

Barda, N, Canetti, M, Gilboa, M, Asraf, K, Indenboim, V, Weiss-Ottolenghi, Y, Amit, S, Zubli, D, Doolman, R, Mendelson, E, Freedman, LS, Kreiss, Y , Lustig, Y & Regev-Yochay, G 2023, 'The Association between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection', Clinical Infectious Diseases, vol. 76, no. 7, pp. 1315-1317. https://doi.org/10.1093/cid/ciac886

TY - JOUR

T1 - The Association between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

AU - Barda, Noam

AU - Canetti, Michal

AU - Gilboa, Mayan

AU - Asraf, Keren

AU - Indenboim, Victoria

AU - Weiss-Ottolenghi, Yael

AU - Amit, Sharon

AU - Zubli, Daniel

AU - Doolman, Ram

AU - Mendelson, Ella

AU - Freedman, Laurence S.

AU - Kreiss, Yitshak

AU - Lustig, Yaniv

AU - Regev-Yochay, Gili

PY - 2023/4/1

Y1 - 2023/4/1

N2 - The correlation between anti–severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre–fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%–59%) for each 10-fold increase in prebooster levels. Prebooster antibody levels could be used to optimally time boosters.

AB - The correlation between anti–severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre–fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%–59%) for each 10-fold increase in prebooster levels. Prebooster antibody levels could be used to optimally time boosters.

KW - IgG levels

KW - SARS-CoV-2

KW - boosters

KW - infection risk

KW - mRNA vaccines

UR - http://www.scopus.com/inward/record.url?scp=85143085583&partnerID=8YFLogxK

U2 - 10.1093/cid/ciac886

DO - 10.1093/cid/ciac886

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 36366729

AN - SCOPUS:85143085583

SN - 1058-4838

VL - 76

SP - 1315

EP - 1317

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 7

ER -

The Association between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Abstract

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this